{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT03133299",
      "orgStudyIdInfo": {
        "id": "Pulm.Med/2017/002"
      },
      "organization": {
        "fullName": "Post Graduate Institute of Medical Education and Research, Chandigarh",
        "class": "OTHER"
      },
      "briefTitle": "A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma",
      "officialTitle": "A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma"
    },
    "statusModule": {
      "statusVerifiedDate": "2018-08",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2016-12-01",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2018-06-30",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2018-06-30",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2017-04-21",
      "studyFirstSubmitQcDate": "2017-04-27",
      "studyFirstPostDateStruct": {
        "date": "2017-04-28",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2018-08-22",
      "lastUpdatePostDateStruct": {
        "date": "2018-08-23",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "PRINCIPAL_INVESTIGATOR",
        "investigatorFullName": "Ritesh Agarwal",
        "investigatorTitle": "Consultant, Department of Pulmonary Medicine, Principal Investigator, Clinical Professor",
        "investigatorAffiliation": "Post Graduate Institute of Medical Education and Research, Chandigarh"
      },
      "leadSponsor": {
        "name": "Post Graduate Institute of Medical Education and Research, Chandigarh",
        "class": "OTHER"
      }
    },
    "oversightModule": {
      "oversightHasDmc": true,
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "Allergic bronchopulmonary aspergillosis (ABPA) is a immunological pulmonary disorder caused by hypersensitive reaction to spores of Aspergillus fumigatus. The prevalence of disease is about 1-2% in asthmatics and 2-15% in patients with cystic fibrosis. The interest in ABPA stems from the fact that the disease is glucocorticoid-sensitive and early treatment can prevent progression to end-stage lung disease. Recently anti-Th2 therapies have been suggested as treatment for ABPA. Vitamin D has been shown to suppress the Th2 responses and decrease the levels of Th2 interleukins. Hence, the investigators propose to assess the role of vitamin D in treating ABPA.",
      "detailedDescription": "Allergic bronchopulmonary aspergillosis (ABPA) is a immunological pulmonary disorder caused by hypersensitive reaction to spores of Aspergillus fumigatus. The prevalence of disease is about 1-2% in asthmatics and 2-15% in patients with cystic fibrosis. The interest in ABPA stems from the fact that the disease is glucocorticoid-sensitive and early treatment can prevent progression to end-stage lung disease.\n\nSystemic steroids remain the mainstay of treatment in ABPA. Antifungal agents are also useful as they reduce fungal load. Newer therapies like omalizumab (anti immunoglobulin E \\[IgE\\] antibody), inhalational amphotericin and Anti Th2 therapies are being studied.\n\nIn pathogenesis of ABPA, there is heightened Th2 activity as a result of type 1 hypersensitive reaction to Aspergillus fumigatus and levels of Th2 cytokines like IL-3, IL-5 and IL-13 and IgE levels are increased in patients with ABPA compared with asthma patients without ABPA.\n\nRecently anti Th2 therapies have been suggested as treatment for ABPA. Vitamin D has been shown to suppress the Th2 immunity and decrease the levels of Th2 interleukins. Hence, the investigators propose to assess the role of vitamin D in treatment of ABPA."
    },
    "conditionsModule": {
      "conditions": [
        "Allergic Bronchopulmonary Aspergilloses"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 30,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Glucocorticoid group",
          "type": "ACTIVE_COMPARATOR",
          "description": "Oral prednisolone 0.5 mg/kg/day for four weeks, 0.25 mg/kg/day for four weeks followed by 0.125 mg/kg/day for four weeks. Prednisolone will then be tapered by 5 mg every two weeks and discontinued. The total duration of glucocorticoids will be four months",
          "interventionNames": [
            "Drug: Glucocorticoids"
          ]
        },
        {
          "label": "Vitamin D plus Glucocorticoid group",
          "type": "EXPERIMENTAL",
          "description": "Oral vitamin D3 tablet, 60,000 IU weekly for 2 months (8 doses) along with Oral prednisolone 0.5 mg/kg/day for four weeks, 0.25 mg/kg/day for four weeks followed by 0.125 mg/kg/day for four weeks. Prednisolone will then be tapered by 5 mg every two weeks and discontinued. The total duration of glucocorticoids will be four months",
          "interventionNames": [
            "Drug: Glucocorticoids",
            "Drug: Vitamin D"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Glucocorticoids",
          "description": "Oral prednisolone for four months",
          "armGroupLabels": [
            "Glucocorticoid group",
            "Vitamin D plus Glucocorticoid group"
          ]
        },
        {
          "type": "DRUG",
          "name": "Vitamin D",
          "description": "Oral vitamin D for two months",
          "armGroupLabels": [
            "Vitamin D plus Glucocorticoid group"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Decline in total IgE",
          "description": "Total IgE at baseline and two months",
          "timeFrame": "Two months"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Decline in total IgE",
          "description": "Total IgE at baseline and four months",
          "timeFrame": "Four months"
        },
        {
          "measure": "Decline in total IgE",
          "description": "Total IgE at baseline and six months",
          "timeFrame": "Six months"
        },
        {
          "measure": "Th1/Th2 cytokines",
          "description": "Th1 (IL-2 and interferon-gamma) and Th2 (IL4, IL5, IL10) cytokines at baseline and two months",
          "timeFrame": "Two months"
        },
        {
          "measure": "Th1/Th2 cytokines",
          "description": "Th1 (IL-2 and interferon-gamma) and Th2 (IL4, IL5, IL10) cytokines at baseline and four months",
          "timeFrame": "Four months"
        },
        {
          "measure": "Th1/Th2 cytokines",
          "description": "Th1 (IL-2 and interferon-gamma) and Th2 (IL4, IL5, IL10) cytokines at baseline and six months",
          "timeFrame": "Six months"
        },
        {
          "measure": "Time to first exacerbation",
          "description": "The time to first exacerbation will be noted in the two groups",
          "timeFrame": "One year"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of ABPA as per the International Society for Human and Animal Mycology Working group criteria\n* Treatment na√Øve\n\nExclusion Criteria:\n\n* Failure to provide informed consent\n* Enrollment in another trial of ABPA\n* Pregnancy\n* Creatinine more than or equal to 1.5 mg/dL\n* Immunosuppressive states like chronic liver disease, chronic renal failure, cytotoxic therapy, uncontrolled diabetes mellitus and others",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "65 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "locations": [
        {
          "facility": "Postgraduate Institute of Medical Education and Research",
          "city": "Chandigarh",
          "zip": "160012",
          "country": "India",
          "geoPoint": {
            "lat": 30.73629,
            "lon": 76.7884
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "30561849",
          "type": "DERIVED",
          "citation": "Dodamani MH, Muthu V, Thakur R, Pal A, Sehgal IS, Dhooria S, Aggarwal AN, Garg M, Chakrabarti A, Agarwal R. A randomised trial of vitamin D in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Mycoses. 2019 Apr;62(4):320-327. doi: 10.1111/myc.12879. Epub 2019 Feb 5."
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "UNDECIDED"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D001229",
          "term": "Aspergillosis, Allergic Bronchopulmonary"
        }
      ],
      "ancestors": [
        {
          "id": "D055732",
          "term": "Pulmonary Aspergillosis"
        },
        {
          "id": "D001228",
          "term": "Aspergillosis"
        },
        {
          "id": "D009181",
          "term": "Mycoses"
        },
        {
          "id": "D001423",
          "term": "Bacterial Infections and Mycoses"
        },
        {
          "id": "D007239",
          "term": "Infections"
        },
        {
          "id": "D008172",
          "term": "Lung Diseases, Fungal"
        },
        {
          "id": "D012141",
          "term": "Respiratory Tract Infections"
        },
        {
          "id": "D008171",
          "term": "Lung Diseases"
        },
        {
          "id": "D012140",
          "term": "Respiratory Tract Diseases"
        },
        {
          "id": "D012130",
          "term": "Respiratory Hypersensitivity"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D005938",
          "term": "Glucocorticoids"
        },
        {
          "id": "D014807",
          "term": "Vitamin D"
        }
      ],
      "ancestors": [
        {
          "id": "D000305",
          "term": "Adrenal Cortex Hormones"
        },
        {
          "id": "D006728",
          "term": "Hormones"
        },
        {
          "id": "D006730",
          "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
        },
        {
          "id": "D045505",
          "term": "Physiological Effects of Drugs"
        },
        {
          "id": "D020228",
          "term": "Pharmacologic Actions"
        },
        {
          "id": "D020164",
          "term": "Chemical Actions and Uses"
        },
        {
          "id": "D012632",
          "term": "Secosteroids"
        },
        {
          "id": "D013256",
          "term": "Steroids"
        },
        {
          "id": "D000072473",
          "term": "Fused-Ring Compounds"
        },
        {
          "id": "D011083",
          "term": "Polycyclic Compounds"
        }
      ]
    }
  },
  "hasResults": false
}